1
|
Doganc F, Ozkan T, Farhangzad N, Mavideniz A, Celik I, Sunguroglu A, Göker H. Synthesis of novel indol-3-acetamido analogues as potent anticancer agents, biological evaluation and molecular modeling studies. Bioorg Chem 2024; 148:107429. [PMID: 38728910 DOI: 10.1016/j.bioorg.2024.107429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2024] [Revised: 04/21/2024] [Accepted: 05/04/2024] [Indexed: 05/12/2024]
Abstract
Cannabinoids bind to cannabinoid receptors CB1 and CB2 and their antitumoral activity has been reported against some various cancer cell lines. Some synthetic cannabinoids possessing indole rings such as JWH-015 and JWH-133 particularly bind to the cannabinoid CB2 receptor and it was reported that they inhibit the proliferation and growth of various cancer cells without their psychoactive effects. However, the pharmacological action mechanisms of the cannabinoids are completely unknown. In this study, we report the synthesis of some new cannabinoidic novel indoles and evaluate their anticancer activity on various cancerous and normal cell lines (U87, RPMI 8226, HL60 and L929) using several cellular and molecular assays including MTT assay, real-time q-PCR, scratch assay, DAPI assay, Annexin V-PE/7AAD staining, caspase3/7 activity tests. Our findings indicated that compounds 7, 10, 13, 16, and 17 could reduce cell viability effectively. Compound 17 markedly increased proapoptotic genes (BAX, BAD, and BIM), tumor suppressor gene (p53) expression levels as well as the BAX/BCL-2 ratio in U87 cells. In addition, 17 inhibited cell migration. Based on these results, 17 was chosen for determining the mechanism of cell death in U87 cells. DAPI and Annexin V-7AAD staining results showed that 17 induced apoptosis, moreover activated caspase 3/7 significantly. Hence, compound 17, was selected as a lead compound for further pharmacomodulation. To rationalize the observed biological activities of 17, our study also included a comprehensive analysis using molecular docking and MD simulations. This integrative approach revealed that 17 fits tightly into the active site of the CB2 receptor and is involved in key interactions that may be responsible for its anti-proliferative effects.
Collapse
Affiliation(s)
- Fatima Doganc
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara 06560, Turkey
| | - Tulin Ozkan
- Department of Medical Biology, Faculty of Medicine, Ankara University, Ankara, Turkey
| | - Nazila Farhangzad
- Department of Medical Biology, Faculty of Medicine, Ankara University, Ankara, Turkey; Graduate School of Health Sciences, Ankara University, Dışkapı, Ankara, Turkey
| | - Acelya Mavideniz
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara 06560, Turkey; Graduate School of Health Sciences, Ankara University, Dışkapı, Ankara, Turkey
| | - Ismail Celik
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, Kayseri 38280, Turkey
| | - Asuman Sunguroglu
- Department of Medical Biology, Faculty of Medicine, Ankara University, Ankara, Turkey
| | - Hakan Göker
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara 06560, Turkey.
| |
Collapse
|
2
|
Wu YR, Tang JQ, Zhang WN, Zhuang CL, Shi Y. Rational drug design of CB2 receptor ligands: from 2012 to 2021. RSC Adv 2022; 12:35242-35259. [PMID: 36540233 PMCID: PMC9730932 DOI: 10.1039/d2ra05661e] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2022] [Accepted: 12/03/2022] [Indexed: 08/29/2023] Open
Abstract
Cannabinoid receptors belong to the large family of G-protein-coupled receptors, which can be divided into two receptor types, cannabinoid receptor type-1 (CB1) and cannabinoid receptor type-2 (CB2). Marinol, Cesamet and Sativex are marketed CB1 drugs which are still in use and work well, but the central nervous system side effects caused by activation CB1, which limited the development of CB1 ligands. So far, no selective CB2 ligand has been approved for marketing, but lots of its ligands in the clinical stage and pre-clinical stage have positive effects on the treatment of some disease models and have great potential for development. Most selective CB2 agonists are designed and synthesized based on non-selective CB2 agonists through the classical med-chem strategies, e.g. molecular hybridization, scaffold hopping, bioisosterism, etc. During these processes, the balance between selectivity, activity, and pharmacokinetic properties needs to be achieved. Hence, we summarized some reported ligands on the basis of the optimization strategies in recent 10 years, and the limitations and future directions.
Collapse
Affiliation(s)
- Yan-Ran Wu
- School of Pharmacy, Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Medical University 1160 Shengli Street Yinchuan 750004 China
| | - Jia-Qin Tang
- School of Pharmacy, Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Medical University 1160 Shengli Street Yinchuan 750004 China
| | - Wan-Nian Zhang
- School of Pharmacy, Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Medical University 1160 Shengli Street Yinchuan 750004 China
- School of Pharmacy, Second Military Medical University 325 Guohe Road Shanghai 200433 China
| | - Chun-Lin Zhuang
- School of Pharmacy, Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Medical University 1160 Shengli Street Yinchuan 750004 China
- School of Pharmacy, Second Military Medical University 325 Guohe Road Shanghai 200433 China
| | - Ying Shi
- School of Pharmacy, Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Medical University 1160 Shengli Street Yinchuan 750004 China
| |
Collapse
|
3
|
Mugnaini C, Kostrzewa M, Bryk M, Mahmoud AM, Brizzi A, Lamponi S, Giorgi G, Ferlenghi F, Vacondio F, Maccioni P, Colombo G, Mor M, Starowicz K, Di Marzo V, Ligresti A, Corelli F. Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3- b]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In Vivo. J Med Chem 2020; 63:7369-7391. [PMID: 32515588 DOI: 10.1021/acs.jmedchem.0c00595] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The hallmark of joint diseases, such as osteoarthritis (OA), is pain, originating from both inflammatory and neuropathic components, and compounds able to modulate the signal transduction pathways of the cannabinoid type-2 receptor (CB2R) can represent a helpful option in the treatment of OA. In this perspective, a set of 18 cannabinoid type-2 receptor (CB2R) ligands was developed based on an unprecedented structure. With the aim of improving the physicochemical properties of previously reported 4-hydroxy-2-quinolone-3-carboxamides, a structural optimization program led to the discovery of isosteric 7-hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide derivatives. These new compounds are endowed with high affinity for the CB2R and moderate to good selectivity over the cannabinoid type-1 receptor (CB1R), associated with good physicochemical characteristics. As to the functional activity at the CB2R, compounds able to act either as agonists or as inverse agonists/antagonists were discovered. Among them, compound 51 emerged as a potent CB2R agonist able to reduce pain in rats carrying OA induced by injection of monoiodoacetic acid (MIA).
Collapse
Affiliation(s)
- Claudia Mugnaini
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | - Magdalena Kostrzewa
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council of Italy, Via Campi Flegrei 34, 80078 Pozzuoli, Napoli, Italy.,Institute of Genetics and Biophysics, National Research Council of Italy, Via Pietro Castellino 111, 80131 Napoli, Italy
| | - Marta Bryk
- Institute of Genetics and Biophysics, National Research Council of Italy, Via Pietro Castellino 111, 80131 Napoli, Italy
| | - Ali Mokhtar Mahmoud
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council of Italy, Via Campi Flegrei 34, 80078 Pozzuoli, Napoli, Italy
| | - Antonella Brizzi
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | - Stefania Lamponi
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | - Gianluca Giorgi
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | - Francesca Ferlenghi
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy
| | - Federica Vacondio
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy
| | - Paola Maccioni
- Institute of Neuroscience, National Research Council of Italy, S.S. 554, km 4,500, 09042 Monserrato, Cagliari, Italy
| | - Giancarlo Colombo
- Institute of Neuroscience, National Research Council of Italy, S.S. 554, km 4,500, 09042 Monserrato, Cagliari, Italy
| | - Marco Mor
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy
| | - Katarzyna Starowicz
- Department of Neurochemistry, Institute of Pharmacology, Polish Academy of Sciences, ul. Smetna 12, 31-343 Cracow, Poland
| | - Vincenzo Di Marzo
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council of Italy, Via Campi Flegrei 34, 80078 Pozzuoli, Napoli, Italy
| | - Alessia Ligresti
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council of Italy, Via Campi Flegrei 34, 80078 Pozzuoli, Napoli, Italy
| | - Federico Corelli
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
| |
Collapse
|
4
|
Páez JA, Campillo NE. Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases. Curr Med Chem 2019; 26:3300-3340. [DOI: 10.2174/0929867325666180226095132] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 02/08/2018] [Accepted: 02/15/2018] [Indexed: 02/07/2023]
Abstract
:
The discovery of cannabinoid receptors at the beginning of the 1990s, CB1 cloned
in 1990 and CB2 cloned in 1993, and the availability of selective and potent cannabimimetics
could only be justified by the existence of endogenous ligands that are capable of binding to
them. Thus, the characterisation and cloning of the first cannabinoid receptor (CB1) led to the
isolation and characterisation of the first endocannabinoid, arachidonoylethanolamide (AEA),
two years later and the subsequent identification of a family of lipid transmitters known as the
fatty acid ester 2-arachidonoylglycerol (2-AG).
:
The endogenous cannabinoid system is a complex signalling system that comprises transmembrane
endocannabinoid receptors, their endogenous ligands (the endocannabinoids), the
specific uptake mechanisms and the enzymatic systems related to their biosynthesis and degradation.
:
The endocannabinoid system has been implicated in a wide diversity of biological processes,
in both the central and peripheral nervous systems, including memory, learning, neuronal development,
stress and emotions, food intake, energy regulation, peripheral metabolism, and
the regulation of hormonal balance through the endocrine system.
:
In this context, this article will review the current knowledge of the therapeutic potential of
cannabinoid receptor as a target in Alzheimer’s disease and other less well-known diseases
that include, among others, multiple sclerosis, bone metabolism, and Fragile X syndrome.
:
The therapeutic applications will be addressed through the study of cannabinoid agonists acting
as single drugs and multi-target drugs highlighting the CB2 receptor agonist.
Collapse
Affiliation(s)
- Juan A. Páez
- Instituto de Quimica Medica (IQM-CSIC). C/ Juan de la Cierva, 3, 28006, Madrid, Spain
| | - Nuria E. Campillo
- Centro de Investigaciones Biologicas (CIB-CSIC). C/ Ramiro de Maeztu, 9, 28040, Madrid, Spain
| |
Collapse
|
5
|
Azab ME, Flefel EM, Sabry NM, Amr AEGE. Synthesis and antimicrobial activity of some linear dipeptide pyridine and macrocyclic pentaazapyridine candidates. ZEITSCHRIFT FÜR NATURFORSCHUNG B 2016; 71:803-810. [DOI: 10.1515/znb-2016-0018] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
Abstract
Abstract
A series of tetracarboxamide and macrocyclic tripeptides have been prepared starting from 3,5-bis[N-(1-hydrazinyl-1-oxo-3-phenylpropan-2-yl)]pyridinecarboxamide 4 as starting material, which was synthesized from dinicotinic acid 1. Treatment of 4 with 1,4-diaminobutane, 1,6-diaminohexane, or cycloalkanone derivatives gave the corresponding macrocyclic tetracarboxamides (5a, b) and cycloalkyl hydrazone derivatives (6a–c), respectively. Additionally, the reaction of 4 with acetophenone or acetylpyridine derivatives gave the corresponding Schiff base derivatives 7a–e and 8a–c, respectively. Also, carboxylic acid hydrazide 4 was treated with acid anhydrides in glacial acetic acid to afford the corresponding diimide tetracarboxamide derivatives 9a, b, 10, and 11, respectively. The structures of newly synthesized compounds are established by physical and spectral data evidences. Some of the synthesized compounds were screened as antimicrobial agents.
Collapse
Affiliation(s)
- Mohamed E. Azab
- Department of Chemistry , Faculty of Science, University of Ain Shams , Cairo, Egypt
| | | | | | | |
Collapse
|
6
|
Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists. Eur J Med Chem 2016; 113:11-27. [DOI: 10.1016/j.ejmech.2016.02.032] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2015] [Revised: 01/26/2016] [Accepted: 02/11/2016] [Indexed: 01/01/2023]
|
7
|
El Bouakher A, Le Goff R, Tasserie J, Lhoste J, Martel A, Comesse S. Synthesis of Oxazolidin-4-ones: Domino O-Alkylation/Aza-Michael/Intramolecular Retro-Claisen Condensation. Org Lett 2016; 18:2383-6. [DOI: 10.1021/acs.orglett.6b00851] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Abderrahman El Bouakher
- Normandie Université, UNIHAVRE, URCOM, 76600 Le Havre 25, Rue Philipe Lebon, BP 540, F-76600 Le Havre, France
| | - Ronan Le Goff
- Normandie Université, UNIHAVRE, URCOM, 76600 Le Havre 25, Rue Philipe Lebon, BP 540, F-76600 Le Havre, France
| | - Jordan Tasserie
- Normandie Université, UNIHAVRE, URCOM, 76600 Le Havre 25, Rue Philipe Lebon, BP 540, F-76600 Le Havre, France
| | - Jérôme Lhoste
- Université du Maine, IMMM, UMR 6283 CNRS, 72085 Le Mans, France
| | - Arnaud Martel
- Université du Maine, IMMM, UMR 6283 CNRS, 72085 Le Mans, France
| | - Sébastien Comesse
- Normandie Université, UNIHAVRE, URCOM, 76600 Le Havre 25, Rue Philipe Lebon, BP 540, F-76600 Le Havre, France
| |
Collapse
|
8
|
Aghazadeh Tabrizi M, Baraldi PG, Borea PA, Varani K. Medicinal Chemistry, Pharmacology, and Potential Therapeutic Benefits of Cannabinoid CB2 Receptor Agonists. Chem Rev 2016; 116:519-60. [PMID: 26741146 DOI: 10.1021/acs.chemrev.5b00411] [Citation(s) in RCA: 80] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Mojgan Aghazadeh Tabrizi
- Department of Chemical and Pharmaceutical Sciences and ‡Department of Medical Science, Pharmacology Section, University of Ferrara , Ferrara 44121, Italy
| | - Pier Giovanni Baraldi
- Department of Chemical and Pharmaceutical Sciences and ‡Department of Medical Science, Pharmacology Section, University of Ferrara , Ferrara 44121, Italy
| | - Pier Andrea Borea
- Department of Chemical and Pharmaceutical Sciences and ‡Department of Medical Science, Pharmacology Section, University of Ferrara , Ferrara 44121, Italy
| | - Katia Varani
- Department of Chemical and Pharmaceutical Sciences and ‡Department of Medical Science, Pharmacology Section, University of Ferrara , Ferrara 44121, Italy
| |
Collapse
|
9
|
F. Mohamed S, A. Ibrahie A, E. Amr AEG, M. Abdalla M. SARS-CoV 3C-Like Protease Inhibitors of some Newly Synthesized Substituted Pyrazoles and Substituted Pyrimidines Based on 1-(3-Aminophenyl)-3-(1H-indol-3-yl)prop-2-en-1-one. INT J PHARMACOL 2015. [DOI: 10.3923/ijp.2015.749.756] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
10
|
Aghazadeh Tabrizi M, Baraldi PG, Ruggiero E, Saponaro G, Baraldi S, Romagnoli R, Martinelli A, Tuccinardi T. Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH). Eur J Med Chem 2015; 97:289-305. [DOI: 10.1016/j.ejmech.2015.04.064] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Revised: 04/27/2015] [Accepted: 04/30/2015] [Indexed: 10/23/2022]
|
11
|
Chen X, Zhu D, Wang X, Yan S, Lin J. Cascade reaction synthesis of multisubstituted bicyclic pyridone derivatives. Tetrahedron 2013. [DOI: 10.1016/j.tet.2013.08.052] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
12
|
Han S, Thatte J, Buzard DJ, Jones RM. Therapeutic Utility of Cannabinoid Receptor Type 2 (CB2) Selective Agonists. J Med Chem 2013; 56:8224-56. [DOI: 10.1021/jm4005626] [Citation(s) in RCA: 100] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Sangdon Han
- Department of Medicinal Chemistry, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States
| | - Jayant Thatte
- Department of Medicinal Chemistry, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States
| | - Daniel J. Buzard
- Department of Medicinal Chemistry, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States
| | - Robert M. Jones
- Department of Medicinal Chemistry, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San
Diego, California 92121, United States
| |
Collapse
|
13
|
Aghazadeh Tabrizi M, Baraldi PG, Saponaro G, Moorman AR, Romagnoli R, Preti D, Baraldi S, Ruggiero E, Tintori C, Tuccinardi T, Vincenzi F, Borea PA, Varani K. Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists. J Med Chem 2013; 56:4482-96. [PMID: 23697626 DOI: 10.1021/jm400182t] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We recently described the medicinal chemistry of a new series of heteroaryl-4-oxopyridine/7-oxopyrimidines as CB2 receptor partial agonists, showing that the functionality of these ligands is controlled by the nature of the heteroaryl function condensed with the pyridine ring. We describe herein the design and synthesis of the 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides, structural isomers of our previously reported pyrazolo[3,4-b]pyridines. All of the new compounds showed high affinity and selectivity for the CB2 receptor in the nanomolar range. In 3,5-cyclic adenosine monophosphate (cAMP) assays, the novel series shows stimulatory effects on forskolin-induced cAMP production acting as inverse agonists.
Collapse
Affiliation(s)
- Mojgan Aghazadeh Tabrizi
- Dipartimento di Scienze Chimiche e Farmaceutiche, Università di Ferrara, Via Fossato di Mortara 17-19, 44121 Ferrara, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|